ETHNOPHARMACOLOGICAL RELEVANCE: Trigonella foenum-graecum L. (TFG) is traditionally used to treat diabetes in North Africa. we therefore tested the effects of the hydro-alcoholic extract of TFG seeds in a C57/BL6J mouse model of diabetes induced by a standardised high-fat diet (HFD). MATERIALS AND METHODS: Plant extracts (2 g/kg daily) were administered orally by gavage at the start of HFD, or after confirmation of established diabetes (17th week), for 20 or 18 weeks, respectively, to male C57BL/6J mice. Animals were weighed; food intake and plasma glucose, lipid profile, insulin and insulin resistance were measured. RESULTS: TFG extracts opposed the development of diabetes: compared with untreated HFD mice, TFG-treated HFD mice had lower mean (± SD) plasma glucose (129.3 ± 39.4 vs. 183.1 ± 19.1mg/dL, p<0.05), plasma insulin (1.3 ± 0.8 vs. 3.1 ± 1.8 ng/mL, p<0.05) and triglycerides (18.9 ± 12.9 vs. 48.9 ± 12.1mg/dL, p<0.05), and less insulin resistance as estimated by the homeostasis model assessment (HOMA: 9.7 ± 11.1 vs. 38.3 ± 26.6, p<0.05). In mice with established diabetes, TFG reduced fasting plasma glucose (170.4 ± 24.1 vs. 229.0 ± 20.8 mg/dL, p<0.05), plasma insulin (1.7 ± 1.3 vs. 3.3 ± 14.3 ng/mL, p<0.05) and insulin resistance (HOMA: TFG: 19.2 ± 15.7 vs. HFD control: 38.5 ± 30.3, p<0.05). In addition, administration of TFG extract also caused significant reduction in triglycerides (17.9 ± 9.7 vs. 62.8 ± 18.3 mg/dL, p<0.05) and total cholesterol (1.30 ± 0.20 vs. 1.80 ± 1.10 g/L, p<0.05), and an increase in HDL-cholesterol (1.6 ± 0.2 vs. 1.2 ± 0.1 g/L). The plant extract had no effect on calorie intake or body weight. CONCLUSION: TFG extract opposed the development of experimental HFD diabetes in mice, and had an anti-diabetic effect in mice with established diabetes.
ETHNOPHARMACOLOGICAL RELEVANCE: Trigonella foenum-graecum L. (TFG) is traditionally used to treat diabetes in North Africa. we therefore tested the effects of the hydro-alcoholic extract of TFG seeds in a C57/BL6J mouse model of diabetes induced by a standardised high-fat diet (HFD). MATERIALS AND METHODS: Plant extracts (2 g/kg daily) were administered orally by gavage at the start of HFD, or after confirmation of established diabetes (17th week), for 20 or 18 weeks, respectively, to male C57BL/6J mice. Animals were weighed; food intake and plasma glucose, lipid profile, insulin and insulin resistance were measured. RESULTS:TFG extracts opposed the development of diabetes: compared with untreated HFD mice, TFG-treated HFD mice had lower mean (± SD) plasma glucose (129.3 ± 39.4 vs. 183.1 ± 19.1mg/dL, p<0.05), plasma insulin (1.3 ± 0.8 vs. 3.1 ± 1.8 ng/mL, p<0.05) and triglycerides (18.9 ± 12.9 vs. 48.9 ± 12.1mg/dL, p<0.05), and less insulin resistance as estimated by the homeostasis model assessment (HOMA: 9.7 ± 11.1 vs. 38.3 ± 26.6, p<0.05). In mice with established diabetes, TFG reduced fasting plasma glucose (170.4 ± 24.1 vs. 229.0 ± 20.8 mg/dL, p<0.05), plasma insulin (1.7 ± 1.3 vs. 3.3 ± 14.3 ng/mL, p<0.05) and insulin resistance (HOMA: TFG: 19.2 ± 15.7 vs. HFD control: 38.5 ± 30.3, p<0.05). In addition, administration of TFG extract also caused significant reduction in triglycerides (17.9 ± 9.7 vs. 62.8 ± 18.3 mg/dL, p<0.05) and total cholesterol (1.30 ± 0.20 vs. 1.80 ± 1.10 g/L, p<0.05), and an increase in HDL-cholesterol (1.6 ± 0.2 vs. 1.2 ± 0.1 g/L). The plant extract had no effect on calorie intake or body weight. CONCLUSION:TFG extract opposed the development of experimental HFD diabetes in mice, and had an anti-diabetic effect in mice with established diabetes.
Authors: Asokan Prema; Arokiasamy Justin Thenmozhi; Thamilarasan Manivasagam; Musthafa Mohamed Essa; Mohammed D Akbar; Mohammed Akbar Journal: PLoS One Date: 2016-11-28 Impact factor: 3.240